PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of mconcolMolecular & Cellular Oncology
 
Mol Cell Oncol. 2016; 3(6): e1160854.
Published online 2016 March 28. doi:  10.1080/23723556.2016.1160854
PMCID: PMC5160399

Nuclear reprogramming of cancer stem cells: Corrupting the epigenetic code of cell identity with oncometabolites

ABSTRACT

Generation of cancer stem cell (CSC)-like cells might occur through metabolic corruption of the epigenetic codes that govern cell identity. We recently identified how archetypal oncometabolites, without altering the baseline expression of endogenous stem cell maintenance genes but endowing cells with epigenetic states refractory to differentiation, considerably enhance the global kinetic efficiency of nuclear reprogramming processes that generate CSC-like states de novo. This study highlights that metabolo-epigenetic axes of communication can direct the development and maintenance of CSCs during the natural history of cancer diseases.

KEYWORDS: Cancer stem cells, epigenetics, nuclear reprogramming, oncometabolites

The last 5 years have witnessed significant advances in our understanding of how altered tumor cell metabolism, identified almost a century ago by Otto Warburg, is actually a central contributor to the global process of carcinogenesis rather than being a passive player.1 At the same time, we have quickly amassed in-depth knowledge of the striking “metabolic reprogramming” phenomena that occur in pluripotent embryonic stem cells (ESCs), tissue-specific adult stem cells (ASCs), and induced pluripotent stem cells (iPSCs).2-4 We are beginning to appreciate that “common” metabolites generated during bioenergetic and biosynthetic processes are actively employed in enzymatic reactions that lead to epigenetic modifications and transcriptional gene regulation, a metabolic contribution to global epi-transcriptional changes that ultimately impacts canonical stem cell features such as self-renewal and differentiation.5

The appreciation that metabolites that act as cofactors for histone deacetylation/acetylation and histone/DNA methylation (i.e., S-adenosyl methionine [SAM], acetyl-CoA, α-ketoglutarate [α-KG], flavin adenine dinucleotide [FAD], and nicotinamide adenine nucleotide [NAD+]) can regulate many of the cell fate decisions made by stem cells has firmly established the notion that major metabolic pathways (i.e., one-carbon cycle, glycolysis, tricarboxylic acid cycle, and oxidative phosphorylation) can directly contribute to the chromatin state in stem cells through a metabolo-epigenetic axis of communication. Moreover, exploration of the early metabolic alterations that occur during establishment of pluripotency in iPSCs—without significant changes in gene expression—temptingly suggests that metabolic reprogramming per se may be a molecular pre-requisite for the successful acquisition of a stem cell state. However, the possibility that a metabolically-driven corrupted version of the epigenome might also play a role in directing the so-called cancer stem cells (CSCs), which are thought to bear the majority of a cancer's tumor-initiating, metastatic, and treatment resistance ability, has remained largely unexplored.

We have recently proposed that, beyond the specific bioenergetic/biosynthetic demands of stage-specific cancer cell states such as CSCs, specific classes of elite metabolites and the relative spatio-temporal abundance of common interpreters of the metabolic state (i.e., SAM, acetyl-CoA, α-KG, NAD+) can directly influence the 2 primary epigenetic codes (histone modification and DNA methylation) to causally redirect normal and non-CSC tumor cells toward a CSC-like cellular state. We have coined the term “metabostemness” to describe these metabolic parameters that causally control or functionally substitute the epi-transcriptional programs defining a CSC state.6,7 As such, metabostemness can be understood as the “physiological glue” that metabolically connects all the -omic layers with a self-autonomous but plastic CSC epigenetic quality and, therefore, as a function of observable phenotypes that predates systems biology and its subdisciplines (i.e., genomics, transcriptomics, proteomics, metabolomics) at the level of CSC cellular states. In a first attempt to update our current perception of the regulatory role of metabolic reprogramming in cancer cell fate decisions, we utilized specific metabolites that can be oncogenic by themselves, i.e., small-molecule components (or enantiomers) of normal metabolism termed oncometabolites whose accumulation is sufficient to establish a milieu that initiates and drives carcinogenesis. Because the malignant activity of most oncometabolites likely relies on their ability to epigenetically block differentiation markers,8 we tested the hypothesis that archetypal representatives such as 2-hydroxyglutarate (2-HG) would considerably alter the global kinetic efficiency of nuclear reprogramming-like processes that generate CSC-like cells.

To demonstrate the occurrence of CSC-generating epigenetic events manifesting in response to particular cancer-driving oncometabolites, we used a systems biology approach combining mathematical modeling, computation, and proof-of-concept studies with live cells.9 The oncometabolite 2-HG, without altering the baseline expression of endogenous stem cell maintenance genes but by endowing cells with an enhanced refractoriness to differentiation, rendered fully committed epithelial cells more receptive to the epigenetic rewiring required for the de novo acquisition of a CSC state. Our biomathematical model, which introduced nucleosome modification and epigenetic regulation of cell differentiation genes to account for the direct effects of oncometabolites on nuclear reprogramming, revealed that 2-HG promoted higher efficiency and faster kinetics of the CSC nuclear reprogramming induced by a minimal core of stemness and oncogenic transcription factors (OCT4 and SOX2). The fact that the oncometabolically-driven epigenetic modification of inactive/poised states of lineage-specific genes alone was sufficient to significantly alter the efficiency and speed of nuclear reprogramming strongly suggested that oncometabolite-driven pathologic versions of nuclear reprogramming might promote stemness in cancer tissues.9

It might be argued that, in vivo, the number and complexity of the molecular events required for de novo generation of new stem-like cell types (e.g., chromatin decondensation, loss of differentiation marks, transcriptional activation of stemness genes, suppression of competing cell lineages) should intrinsically prevent the initiation of pathologic versions of nuclear reprogramming phenomena in differentiated tissues, including those of tumors. However, we have learned that premature termination of in vivo nuclear reprogramming upon transient induction of stemness factors may be sufficient to induce a stably transformed state through epigenetic, rather than genetic, mechanisms.10 It therefore seems plausible that the speed and efficiency of pathologic nuclear reprogramming phenomena might be increased in the presence of certain physiologically-biased molecular scenarios that pre-lock cells into more easily reprogrammable cell states in vivo. Indeed, if our assumption that metabolically-driven installation of CSC-like faulty epigenetic programs is a bona fide cancer-promoting event (Fig. 1) is correct, a testable prediction is that those carcinomas in which oncometabolically-driven epigenome rewiring suffices to establish a milieu that initiates carcinogenesis but requires additional cooperating mutations for complete transformation and disease progression must behave as accelerated forms of the oncometabolite-independent versions of the same tumors. Accordingly, 2-HG-overproducing IDH1/2-mutated gliomas, acute myeloid leukemia, and central cartilaginous tumors or succinate-overproducing SDH-mutated paragangliomas tend to present at a younger age than 2-HG- and succinate-negative forms of the same tumors.

Figure 1.
Oncometabolic reprogramming of cancer stem cells: Corrupting the epigenetic codes of cell identity. Figuratively speaking, oncometabolites operate as a corrupted version of the “operating system” (OS) that enables aberrant functioning ...

It might be relevant to evaluate whether organ-, tissue-, or cell-specific aberrant forms of nuclear reprogramming-like epigenetic reorganizations, which appear to drive certain forms of pediatric embryonal tumors, can also be described in terms of an aberrant installation of histone/DNA epigenetic software driven by the yet-to-be discovered oncometabolic facet of well-known hereditary cancer syndromes (e.g., BRCA1/2). Perhaps, and unexpectedly, early-onset cancers driven by mutations in metabolic genes and embryonal tumors driven by epigenetically disorganized developmental signaling cascades might become invaluable models to explore alternative mechanisms of tumor formation and evolution in which, unlike the traditional view solely based on the acquisition of mutations that drive multistage cancer development, metabolic reprogramming of the epigenome might operate to increase both cancer susceptibility and clinical aggressiveness.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

This work was supported by grants from the Ministerio de Ciencia e Innovación (MICINN, Grant SAF2012-38914 to Javier A. Menendez) and the University and Research Grants Management Agency (AGAUR, Grant 2014 SGR229 to Javier A. Menendez), Departament d'Economia I Coneixement, Catalonia, Spain. Tomás Alarcón acknowledges financial support from the MICINN under grant MTM2011-29342 and AGAUR under grant 2014 SGR1307. The authors would like to thank Dr. Kenneth McCreath for editorial support.

References

1. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21: 297-308; PMID:22439925; http://dx.doi.org/10.1016/j.ccr.2012.02.014 [PMC free article] [PubMed] [Cross Ref]
2. Shyh-Chang N, Locasale JW, Lyssiotis CA, Zheng Y, Teo RY, Ratanasirintrawoot S, Zhang J, Onder T, Unternaehrer JJ, Zhu H, et al. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science 2013; 339: 222-6; PMID:23118012; http://dx.doi.org/10.1126/science.1226603 [PMC free article] [PubMed] [Cross Ref]
3. Shiraki N, Shiraki Y, Tsuyama T, Obata F, Miura M, Nagae G, Aburatani H, Kume K, Endo F, Kume S. Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. Cell Metab 2014; 19: 780-94; PMID:24746804; http://dx.doi.org/10.1016/j.cmet.2014.03.017 [PubMed] [Cross Ref]
4. Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 2015; 518: 413-6; PMID:25487152; http://dx.doi.org/10.1038/nature13981 [PMC free article] [PubMed] [Cross Ref]
5. Ryall JG, Cliff T, Dalton S, Sartorelli V. Metabolic Reprogramming of Stem Cell Epigenetics. Cell Stem Cell 2015; 17: 651-62; PMID:26637942; http://dx.doi.org/10.1016/j.stem.2015.11.012 [PMC free article] [PubMed] [Cross Ref]
6. Menendez JA, Alarcón T. Metabostemness: a new cancer hallmark. Front Oncol 2014; 4: 262; PMID:25325014; http://dx.doi.org/10.3389/fonc.2014.00262 [PMC free article] [PubMed] [Cross Ref]
7. Menendez JA, Corominas-Faja B, Cuyàs E, Alarcón T. Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions. Oncoscience 2014; 1: 803-6; PMID:25621295; http://dx.doi.org/10.18632/oncoscience.113 [PMC free article] [PubMed] [Cross Ref]
8. Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab 2012; 16:9-17; PMID:22768835; http://dx.doi.org/10.1016/j.cmet.2012.06.001 [PMC free article] [PubMed] [Cross Ref]
9. Menendez JA, Corominas-Faja B, Cuyàs E, García MG, Fernández-Arroyo S, Fernández AF, Joven J, Fraga MF, Alarcón T Oncometabolic Nuclear Reprogramming of Cancer Stemness. Stem Cell Reports 2016; 6(3):273-83. pii: S2213-6711(15)00377-X; http://dx.doi.org/10.1016/j.stemcr.2015.12.012 [PMC free article] [PubMed] [Cross Ref]
10. Ohnishi K, Semi K, Yamamoto T, Shimizu M, Tanaka A, Mitsunaga K, Okita K, Osafune K, Arioka Y, Maeda T, et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 2014; 156: 663-77; PMID:24529372; http://dx.doi.org/10.1016/j.cell.2014.01.005 [PubMed] [Cross Ref]

Articles from Molecular & Cellular Oncology are provided here courtesy of Taylor & Francis